William Blair forecasts CRISPR Therapeutics will report FY2024 earnings of ($4.66) per share, slightly better than the consensus estimate of ($5.17). The company recently posted Q3 earnings of ($1.01) per share, exceeding expectations, but reported revenues significantly below estimates. Analysts maintain a "Hold" rating on the stock, with a mixed outlook reflected in various price targets.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
